Target | Drug | Indication | Trial | Phase | Regimen | Status | Â |
---|---|---|---|---|---|---|---|
GM-CSFR | Mavrilimumab (CAM-3001) | RA | NCT00771420 | I | MTX + 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, and 10.0Â mg/kg or placebo, single dose | Completed | [121] |
RA | NCT01050998 (EARTH study) | IIa | MTX + 10, 30, 50, and 100Â mg or placebo biweekly for 12Â weeks | Completed | [117] | ||
RA | NCT01706926 (EARTH EXPLORER 1) | IIb | MTX + 30, 100, and 150Â mg or placebo biweekly for 24Â weeks | Completed | |||
RA | NCT01712399 | IIb | Long time safety study (5Â years) MTX + 100Â mg biweekly | Active, not recruiting | |||
RA | NCT01715896 (EARTH EXPLORER 2) | II | MTX + mavrilimumab biweekly or golimumab alternating with placebo | Completed | [128] | ||
GM-CSF | MOR103 | RA | NCT01023256 | Ib/IIa | 0.3, 1.0, and 1.5Â mg/kg or placebo weekly for 4Â weeks | Completed | [116] |
MS | NCT01517282 | Ib | 0.5, 1.0, and 2.0Â mg/kg or placebo biweekly for 10Â weeks | Completed | [115] | ||
GM-CSF | Namilumab (MT203) | RA | NCT01317797 | Ib | 150 and 300Â mg or placebo biweekly, 3 times | Completed | [129] |
RA | NCT02393378 | II | MTX + namilumab or adalimumab for 24Â weeks | Recruiting | [131] | ||
RA | NCT02379091 | II | MTX + 20, 80, and 150Â mg or placebo for 24Â weeks | Recruiting | [130] | ||
Psoriasis | NCT02129777 | II | 40, 100, 160, and 300Â mg or placebo on day 1; 20, 50, 80, and 150Â mg or placebo on days 15, 43, and 71 (followed by open-label extension study) | Recruiting | [132] | ||
GM-CSF | KB003 | RA | NCT00995449 | II | 600Â mg or placebo at weeks 0, 2, 4, 8, and 12 | Terminated | [133] |
Asthma | NCT01603277 | II | 400Â mg or placebo | Completed | Â | ||
GM-CSF | MORAb-022 | RA | NCT01357759 | I | Escalating doses of MORAb-022 or placebo | Completed | [134] |